CY1114155T1 - Πολυμερικες κατασκευες - Google Patents

Πολυμερικες κατασκευες

Info

Publication number
CY1114155T1
CY1114155T1 CY20131100605T CY131100605T CY1114155T1 CY 1114155 T1 CY1114155 T1 CY 1114155T1 CY 20131100605 T CY20131100605 T CY 20131100605T CY 131100605 T CY131100605 T CY 131100605T CY 1114155 T1 CY1114155 T1 CY 1114155T1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
domain
multilateral
constructions
polymerization
Prior art date
Application number
CY20131100605T
Other languages
English (en)
Inventor
Abraham Scaria
Peter Pechan
Samuel Wadsworth
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of CY1114155T1 publication Critical patent/CY1114155T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Πολυμερικές πρωτεΐνες σύντηξης μιας περιοχής όμοιας με την Ιg της F1t-1 καθίστανται λειτουργικές με την προσθήκη ή σύνδεση μιας ρίζας. Ξενιστές που κωδικοποιούν τις πρωτεΐνες σύντηξης και κύτταρα του υποδοχέα που εκφράζουν τις πρωτεΐνες σύντηξης μπορούν να χρησιμοποιηθούν θεραπευτικά ώστε να εμποδίσουν την νεοαγγείωση σε άτομα με παθολογικές καταστάσεις που σχετίζονται με την νεοαγγείωση. Τέτοιες καταστάσεις περιλαμβάνουν ηλικιακή εκφύλιση της ώχρας κηλίδας, καρκίνο, ψωρίαση, πολλαπλασιαστική διαβητική αμφιβληστροειδοπάθεια, άσθμα, ραγοειδίτιδα, οστεοαρθρίτιδα και ρευματοειδή αρθρίτιδα. Τα ίδια μέσα πολυμερισμού που χρησιμοποιούνται για μια περιοχή όμοια με την Ιg της FΙt-1, δηλαδή ένας συνδετήρας και μια επικράτεια πολυμερισμού, μπορούν να χρησιμοποιηθούν για άλλα πολυπεπτίδια συμπεριλαμβανομένων εξωκυτταρικών υποδοχέων, μεταβλητών περιοχών αντισωμάτων, κυτοκινών, χημοκινών και παραγόντων ανάπτυξης.
CY20131100605T 2004-09-13 2013-07-17 Πολυμερικες κατασκευες CY1114155T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60888704P 2004-09-13 2004-09-13
US65820905P 2005-03-04 2005-03-04
EP10165159.4A EP2229956B1 (en) 2004-09-13 2005-09-13 Multimeric constructs

Publications (1)

Publication Number Publication Date
CY1114155T1 true CY1114155T1 (el) 2016-08-31

Family

ID=36060586

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100605T CY1114155T1 (el) 2004-09-13 2013-07-17 Πολυμερικες κατασκευες

Country Status (15)

Country Link
US (4) US7928072B2 (el)
EP (2) EP2229956B1 (el)
JP (1) JP4944032B2 (el)
CN (1) CN101094688B (el)
AT (1) ATE470454T1 (el)
BR (1) BRPI0515264B1 (el)
CY (1) CY1114155T1 (el)
DE (1) DE602005021811D1 (el)
DK (2) DK2229956T3 (el)
ES (2) ES2407859T3 (el)
IL (2) IL181839A0 (el)
MX (1) MX2007002942A (el)
PL (2) PL2229956T3 (el)
PT (2) PT1804835E (el)
WO (1) WO2006031689A2 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2229956T3 (da) * 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
EP2203476B1 (en) 2007-09-25 2016-10-26 Genzyme Corporation Compositions and methods for inhibiting interleukin pathways
JP2011512417A (ja) * 2008-02-20 2011-04-21 ジェンザイム・コーポレーション 血管形成の阻害
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
US8697654B2 (en) * 2008-12-18 2014-04-15 E I Du Pont De Nemours And Company Peptide linkers for effective multivalent peptide binding
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
MY180616A (en) 2011-06-30 2020-12-03 Genzyme Corp Inhibitors of t-cell activation
WO2013028541A1 (en) * 2011-08-19 2013-02-28 Children's Medical Center Corporation Vegf-binding protein for blockade of angiogenesis
CN102399292A (zh) * 2011-09-14 2012-04-04 盛剑鹏 重组干细胞因子与免疫球融合蛋白及其制备
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
EP2844267A4 (en) * 2012-04-25 2016-02-24 Ligacept Llc BROAD SPECTRUM ERBB LIGAND BINDING MOLECULES AND METHODS OF USING THE SAME
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014001325A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
RU2692652C2 (ru) 2013-03-13 2019-06-25 Джензим Корпорейшн Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
TWI687225B (zh) 2014-02-06 2020-03-11 美商健臻公司 用於治療及預防黃斑部病變的組成物及方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
EP3253797A4 (en) * 2015-02-03 2018-10-03 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN112368293A (zh) 2018-05-15 2021-02-12 英特肽治疗有限公司 活化剂
CN111655734A (zh) * 2019-04-28 2020-09-11 广州市雷德生物科技有限公司 一种促进蛋白二聚体形成的拉链扣结构及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CN116370399A (zh) * 2021-12-31 2023-07-04 康码（上海）生物科技有限公司 用于病毒的防护和/或治疗的膜剂及其应用
WO2024029876A1 (ko) 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
AU2024322540A1 (en) 2023-08-04 2026-03-05 Panolos Bioscience, Inc. Conjugate of modified fusion protein and scfv, and use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH03233530A (ja) 1990-02-09 1991-10-17 Fuji Photo Optical Co Ltd カメラ
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
AU684498B2 (en) 1993-03-25 1997-12-18 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en) 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2189067A1 (en) 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5747471A (en) 1994-12-09 1998-05-05 Genzyme Corporation Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5910487A (en) 1994-12-09 1999-06-08 Genzyme Corporation Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5939401A (en) 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
DE69628744D1 (de) 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
CA2239366A1 (en) 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
DE69736860T2 (de) 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
JP3837748B2 (ja) 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
US5925628A (en) 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en) 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
EP1173191A4 (en) 1997-05-13 2004-12-01 Univ California NEW ANTIANGIOGENIC PEPTIDAGENTS AND THEIR THERAPEUTIC AND DIAGNOSTIC USE
US5952916A (en) 1998-05-28 1999-09-14 Atras Auto Co., Ltd Hammer-equipped emergency signal device
US7011973B1 (en) 1997-06-03 2006-03-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo and uses thereof
ES2292204T3 (es) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
US5963622A (en) 1997-07-29 1999-10-05 3Com Corporation Mode signalling method and apparatus
CA2303768C (en) 1997-09-19 2009-11-24 The Trustees Of The University Of Pennsylvania Methods and vector constructs useful for production of recombinant aav
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
AU3755900A (en) 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN100523187C (zh) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
WO2002024234A2 (en) 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2002055106A2 (en) 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2434996A1 (en) * 2001-01-25 2002-08-01 Hill-Rom Services, Inc. Hydraulic actuator apparatus for a surgical table
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
US7078411B2 (en) * 2001-05-16 2006-07-18 Umdnj (Univ Of Medicine & Dentist. Of Nj) Phospholipid transfer protein (PLTP) and cholestoral metabolism
NZ535100A (en) 2002-03-20 2008-04-30 Univ Florida RAAV vector compositions and methods for the treatment of choroidal neovascularization
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
DK2229956T3 (da) * 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
BRPI0518105A (pt) 2004-12-17 2008-11-04 Genentech Inc uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers

Also Published As

Publication number Publication date
EP1804835B9 (en) 2010-09-29
ES2347340T3 (es) 2010-10-28
US20110268735A1 (en) 2011-11-03
EP2229956B1 (en) 2013-04-24
EP1804835A4 (en) 2008-07-30
DK1804835T3 (da) 2010-10-11
CN101094688A (zh) 2007-12-26
US20180155417A1 (en) 2018-06-07
EP2229956A1 (en) 2010-09-22
WO2006031689A3 (en) 2006-07-06
WO2006031689A2 (en) 2006-03-23
JP4944032B2 (ja) 2012-05-30
IL216095A (en) 2013-10-31
DE602005021811D1 (de) 2010-07-22
IL181839A0 (en) 2007-07-04
US20070224178A1 (en) 2007-09-27
BRPI0515264A (pt) 2008-07-15
MX2007002942A (es) 2008-03-05
ES2407859T3 (es) 2013-06-14
DK2229956T3 (da) 2013-07-29
EP1804835B1 (en) 2010-06-09
PT1804835E (pt) 2010-10-04
US7928072B2 (en) 2011-04-19
US9815892B2 (en) 2017-11-14
HK1144663A1 (en) 2011-03-04
US8658602B2 (en) 2014-02-25
PT2229956E (pt) 2013-07-31
ATE470454T1 (de) 2010-06-15
BRPI0515264B1 (pt) 2018-12-18
CN101094688B (zh) 2013-05-01
PL1804835T3 (pl) 2010-11-30
EP1804835A2 (en) 2007-07-11
JP2008512127A (ja) 2008-04-24
US20140193411A1 (en) 2014-07-10
PL2229956T3 (pl) 2013-09-30
IL216095A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CY1114155T1 (el) Πολυμερικες κατασκευες
CY1117241T1 (el) Αντισωματα anti-igf
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
MX2020006409A (es) Moléculas de unión al antígeno específicas para ror1.
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
MX2021004660A (es) Moleculas de union multivalentes a base de igm- e iga-fc.
CY1124835T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
EP4342912A3 (en) Binding molecules that modulate a biological activity expressed by a cell
CY1119755T1 (el) Πρωτεϊνες δεσμευομενες με ανθρωπινο αντιγονο c-fms
CY1116037T1 (el) Αντισωματα κατα της ακτιβινης α και χρησεις αυτων
EA200301146A2 (ru) Слитые белки taci-иммуноглобулина
IN2015DN01361A (el)
WO2006038027A3 (en) SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR
NZ602161A (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CY1119591T1 (el) Πρωτεϊνες ειδικης συνδεσης και χρησεις αυτων
EA202190542A1 (ru) Сконструированные биспецифические белки
CY1118829T1 (el) Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων
IS7677A (is) Mótlyf Nogo-viðtaka
MX375426B (es) Direccionamiento de antagonistas de citocinas.
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2016179518A3 (en) Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
CY1119774T1 (el) Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2
CY1115960T1 (el) Θεραπευτικη αγωγη ογκων χρησιμοποιωντας ειδικο αντισωμα anti-l1
EA200800696A1 (ru) Полипептиды и антитела
CY1118797T1 (el) Ανταγωνιστες toll-ωδους υποδοχεα 3